Alkermes (ALKS) Projected to Post Quarterly Earnings on Thursday

Alkermes (NASDAQ:ALKS - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $379.74 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Investors that wish to register for the company's conference call can do so using this link.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Price Performance

ALKS stock traded down $0.11 on Friday, reaching $35.89. 2,626,767 shares of the company's stock were exchanged, compared to its average volume of 1,335,446. The stock has a fifty day moving average of $30.40 and a 200-day moving average of $28.81. Alkermes has a twelve month low of $22.90 and a twelve month high of $36.25. The firm has a market cap of $5.81 billion, a PE ratio of 18.41, a P/E/G ratio of 1.83 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insider Activity

In other news, SVP Christian Todd Nichols sold 5,208 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now owns 23,013 shares in the company, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 323,608 shares of company stock worth $10,854,725 over the last three months. 4.89% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on ALKS shares. Deutsche Bank Aktiengesellschaft started coverage on Alkermes in a report on Tuesday, February 11th. They set a "buy" rating and a $40.00 price objective on the stock. Mizuho upped their price objective on Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. StockNews.com raised Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday. The Goldman Sachs Group upped their price objective on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday. Finally, Piper Sandler reiterated an "overweight" rating and set a $37.00 target price (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $37.25.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.